Owlstone Medical has announced the launch of its Breath Biopsy Kits.
The new product range allows academic, clinical and pharmaceutical researchers to quickly discover and validate breath-based biomarkers in early detection and precision medicine research activities.
Owlstone Medical’s Breath Biopsy platform is a new diagnostic modality capable of detecting biomarkers of disease, and also exogenous compounds, such as volatile drug metabolites, in breath.
The company’s ReCIVA Breath Sampler and new Breath Biopsy Kits ensure consistent and reliable collection of breath samples.
